Collective Family Office LLC Sells 3,917 Shares of Novo Nordisk A/S (NYSE:NVO)

Collective Family Office LLC cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 61.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,499 shares of the company’s stock after selling 3,917 shares during the quarter. Collective Family Office LLC’s holdings in Novo Nordisk A/S were worth $215,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in NVO. Envestnet Asset Management Inc. raised its stake in Novo Nordisk A/S by 1.4% in the second quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock valued at $607,242,000 after buying an additional 58,935 shares during the period. Raymond James & Associates increased its holdings in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares during the last quarter. Natixis Advisors LLC lifted its holdings in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the last quarter. International Assets Investment Management LLC boosted its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the period. Finally, DSM Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 2.3 %

Shares of Novo Nordisk A/S stock traded up $1.95 on Wednesday, hitting $85.29. 3,861,972 shares of the company’s stock traded hands, compared to its average volume of 6,442,661. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a fifty day moving average of $101.94 and a two-hundred day moving average of $120.27. The company has a market capitalization of $382.74 billion, a price-to-earnings ratio of 27.60, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.